Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2017

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents

Résumé

Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. The process that leads these two proteins to aggregate is complex and is the subject of current studies. After a brief description of the aggregation mechanisms, we will provide an overview of new therapeutic agents targeting the different dysfunctions and toxic species found during aggregation
Fichier non déposé

Dates et versions

hal-02043725 , version 1 (21-02-2019)

Identifiants

Citer

Marie Jouanne, Sylvain Rault, Anne-Sophie Voisin-Chiret. Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. European Journal of Medicinal Chemistry, 2017, 139, pp.153-167. ⟨10.1016/j.ejmech.2017.07.070⟩. ⟨hal-02043725⟩
42 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More